SPN003 / SPN004
Candidate drug screening is going to be completed.
SPN003/SPN004 are innovative peptide drugs with synergistic effect on target, with metabolic diseases including type 2 diabetes and obesity as the main indications.
Candidate drug screening has been completed, preclinical studies are under way.
SPN007 is a new polypeptide drug with proprietary intellectual property rights. Its indications have expanded from simply lowering blood glucose levels in type 2 diabetes to treating obesity and non-alcoholic fatty liver disease (NASH).
At the stage of preclinical studies.
Spn009 is an innovative long-acting hypoglycemic drug for type 2 diabetes mellitus.
At the stage of candidate drug screening.
SPN-X is a peptide inhibitor against the novel coronavirus main protease.